Search

My Top Five: Promising gene therapies for ocular conditions

Gene therapy, a pivotal advancement in modern medicine, particularly shines in ophthalmology. By targeting defective genes with engineered vectors, this approach promises significant strides in treating inherited retinal diseases. This article reviews the top five gene therapies in late-stage trials,...

Refined glaucoma referral practice offers prospect of improved capacity and expanded role for primary eye care professionals

Glaucoma is the most frequent cause of irreversible blindness worldwide and the second leading cause of blindness in the UK [1,2]. The global prevalence of glaucoma in 2010 was approximately 3.5% for people aged 40-80 years, according to Jonas et...

Back-to-back congresses in Africa highlight international collaboration to advance eye health

The ISOO Africa 2023 Congress The first International Society of Ocular Oncology (ISOO) [1] conference to be held in Africa took place in Mombasa, Kenya, from 21-23 August 2023. Participants came from all over Africa, as well as the US,...

Well-presented scholarly research work will reduce chances of journal rebuttal

Submitting to an academic journal? Are you aware of the requirements and constraints of relevant copyright laws? Rod McNeil provides a guide for aspiring authors. Getting published in peer-reviewed academic and medical journals is not easy. But careful attention to...

The science of glaucoma management: highlights of the 2020 Moorfields International Glaucoma Symposium

Held earlier this year, the 12th annual Moorfields International Glaucoma Symposium provided a forum for advanced clinical and scientific exchange in glaucoma management. The authors describe the key presentation themes and debates, highlighting specific topics of interest to glaucoma specialists....

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...